title: How cost-effective is the treatment of dyslipidemia in patients with diabetes but without cardiovascular disease? A response to Grover et al.
authors: L E
authors: LE
authors: Egede
mesh_terms: D002318:Cardiovascular Diseases; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D048909:Diabetes Complications; D003920:Diabetes Mellitus / Q000503:physiopathology / Q000523:psychology; D005260:Female; D006801:Humans; D006949:Hyperlipidemias / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D008297:Male; D009017:Morbidity; D011788:Quality of Life; D019057:Quality-Adjusted Life Years; D019821:Simvastatin / Q000627:therapeutic use*
chemical_list: D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D000960:Hypolipidemic Agents; D019821:Simvastatin